Assembly Biosciences Inc (ASMB)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Assembly Biosciences Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 25.10 $ — 35% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year -29.1% failed
- Share count grows by less than 3% a year 40.6% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 96.6% passed
- Gross margin at 40% or higher and without meaningful erosion 99.8% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 245 m net cash passed
- Operating cash flow covers the profits of the last three years 38 m failed
- Return on capital at 15% or higher, or up versus two years ago -5.8% failed
- Insiders hold at least 10% or are net buyers 28.4% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 99.2% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 2
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.14 | -1.62 – 1.90 | 46 | 125.4% | 2 |
| 12/31/2027 | -2.11 | -3.44 – -0.77 | 32 | -1,603.6% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.70 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.52 | – | 7 | 2.70 | -140.50 | 0 | 0 |
| 2025: Q1 | -0.44 | – | 9 | 62.80 | -93.60 | -23 | -23 |
| 2025: Q2 | -0.51 | – | 10 | 12.80 | -105.90 | -17 | -17 |
| 2025: Q3 | -0.46 | – | 11 | 57.60 | -85.20 | -15 | -15 |
| 2025: Q4 | 1.11 | – | 43 | 477.30 | 52.00 | 14 | 14 |
| 2026: Q1 | -0.46 | – | 8 | -12.80 | -110.50 | -22 | -22 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -45 | -44 | -25.69 | -35 | 80 | 98 |
| 2017 | 9 | -52 | -43 | -24.12 | 2 | 113 | 169 |
| 2018 | 15 | -93 | -91 | -39.80 | -65 | 211 | 268 |
| 2019 | 16 | -103 | -98 | -27.83 | -84 | 273 | 348 |
| 2020 | 79 | -65 | -62 | -15.66 | -63 | 241 | 283 |
| 2021 | 6 | -133 | -130 | -36.00 | -93 | 169 | 191 |
| 2022 | 0 | -94 | -92 | -22.82 | -84 | 83 | 102 |
| 2023 | 7 | -65 | -61 | -13.38 | 23 | 41 | 137 |
| 2024 | 29 | -45 | -40 | -6.69 | -51 | 33 | 119 |
| 2025 | 72 | -12 | -6 | -0.55 | -41 | 207 | 258 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Assembly Biosciences, Inc., ein Biotechnologieunternehmen, entwickelt weltweit Therapiekandidaten zur Behandlung von Viruserkrankungen.
| Employees | 73 |
|---|---|
| Headquarters | South San Francisco, CA |
| Address | Two Tower Place, 94080 South San Francisco, United States |
| Phone | 833 509 4583 |
| Website | assemblybio.com |
| IPO Date | 17. Dec 2010 |
| ISIN | US0453962070 |
| Stock Split | 1:12 on 02/12/2024 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jason A. Okazaki J.D. | CEO, President & Director | 1976 |
| William E. Delaney IV, Ph.D. | Chief Scientific Officer | 1972 |
| Anuj Gaggar M.D., Ph.D. | Chief Medical Officer | 1978 |
| Jeanette M. Bjorkquist | Principal Financial Officer, Executive Director of Accounting & Treasury | 1987 |
| Shannon Ryan | Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management | – |
| Jennifer A. Troia MHROD, SHRM-SCP, SPHR | Chief Human Resources Officer | – |
| Nicole S. White Ph.D. | Chief Manufacturing Officer | 1980 |
| Katie Kitrinos | Senior VP of Preclinical Research & Development | – |
| Thomas E. Rollins | Executive Officer | 1956 |
| Amy Figueroa C.F.A. | Investor Relations Consultant | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.